Scientists comment on phase 3 results from the INTerpath-001 trial looking at an mRNA vaccine for melanoma. Dr Lennard … read more
expert reaction to top line results from the Phase 3 INTerpath-001 trial looking at an mRNA vaccine (intismeran) in combination with pembrolizumab for patients with completely resected stage IIB-IV melanoma
Science Media Centre